/MOC.WA
MOC.WA Stock - Molecure S.A.
Healthcare|BiotechnologyWSE
$6.36+3.08%
+$0.19 (+3.08%) • Dec 23
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MOC.WA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.30 – $6.42
TARGET (TP)$7.31
STOP LOSS$5.85
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.79
52W High$10.70
52W Low$5.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.92M | $100 | $7.51M | $400 | $122.94M |
| Gross Profit | $-489,909 | $-4,101,610 | $-21,328 | $-2,773,090 | $84.53M |
| Gross Margin | -16.8% | -4101610.0% | -0.3% | -693272.5% | 68.8% |
| Operating Income | $-33,609,047 | $-32,128,045 | $-43,908,448 | $-13,764,299 | $73.70M |
| Net Income | $-31,287,928 | $-28,373,117 | $-13,539,992 | $-13,642,556 | $67.96M |
| Net Margin | -1071.8% | -28373117.0% | -180.2% | -3410639.0% | 55.3% |
| EPS | $-1.55 | $-1.69 | $-2.56 | $-0.98 | $5.00 |
Company Overview
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MOC.WABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.26
Q1 2025
EPS Surprise History
Q2 23
No data
Q4 23
No data
Q4 23
No data
Q2 24
No data
Q2 24
No data
Q4 24
No data
Q4 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 27, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | $-0.26 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.52 | — | — |
Q4 2024 | Oct 15, 2024 | — | $-0.37 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.46 | — | — |
Q2 2024 | May 17, 2024 | — | $-0.41 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.40 | — | — |
Q4 2023 | Oct 31, 2023 | — | $-0.25 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.29 | — | — |
Q2 2023 | Apr 27, 2023 | — | $-0.16 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.43 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.11 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.25 | — | — |
Q2 2022 | Apr 29, 2022 | — | $-0.23 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.49 | — | — |
Q4 2021 | Oct 29, 2021 | — | $-0.13 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.20 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.15 | — | — |
Q4 2020 | Dec 31, 2020 | — | $4.76 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-0.06 | — | — |
Latest News
Loading news...
Frequently Asked Questions about MOC.WA
What is MOC.WA's current stock price?
Molecure S.A. (MOC.WA) is currently trading at $6.36 per share. The stock has moved +3.08% today.
What is the analyst price target for MOC.WA?
No analyst price targets are currently available for this stock.
What sector is Molecure S.A. in?
Molecure S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the WSE exchange.
What is MOC.WA's market cap?
Molecure S.A. has a market capitalization of $0.13 billion, making it a small-cap company.
Does MOC.WA pay dividends?
No, Molecure S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAWM.WA
Airway Medix S.A.
$0.33
Mkt Cap: $0.0B
CTX.WA
Captor Therapeutics Spolka Akcyjna
$69.80
Mkt Cap: $0.4B
GMT.WA
Genomtec S.A.
$3.77
Mkt Cap: $0.1B
ICE.WA
Medinice S.A.
$16.96
Mkt Cap: $0.1B
MAB.WA
Mabion S.A.
$6.95
Mkt Cap: $0.1B
NNG.WA
NanoGroup S.A.
$2.60
Mkt Cap: $0.1B
PHR.WA
Pharmena S.A.
$2.55
Mkt Cap: $0.0B
PTG.WA
Poltreg S.A.
$24.60
Mkt Cap: $0.1B
PUR.WA
Pure Biologics Spólka Akcyjna
$3.70
Mkt Cap: $0.0B
URT.WA
Urteste S.A.
$40.00
Mkt Cap: $0.1B
Explore stocks similar to MOC.WA for comparison